Pilot clinical trial of antitumor vaccine with dendritic cells pulsed with multiple HLA-A2 and DP4 peptides and low doses cyclophosphamide to control regulatory T cells, in patients with metastatic lung cancer
Phase I/II study of a re-engineered autologous dendritic cell adjuvant vaccine in resectable non-small cell lung cancer
